It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
An epidemiological association between multiple sclerosis (MS) and inflammatory bowel disease (IBD) is well established, but whether this reflects a shared genetic aetiology, and whether consistent genetic relationships exist between MS and the two predominant IBD subtypes, ulcerative colitis (UC) and Crohn’s disease (CD), remains unclear. Here, we use large-scale genome-wide association study summary data to investigate the shared genetic architecture between MS and IBD overall and UC and CD independently. We find a significantly greater genetic correlation between MS and UC than between MS and CD, and identify three SNPs shared between MS and IBD (rs13428812), UC (rs116555563) and CD (rs13428812, rs9977672) in cross-trait meta-analyses. We find suggestive evidence for a causal effect of MS on UC and IBD using Mendelian randomization, but no or weak and inconsistent evidence for a causal effect of IBD or UC on MS. We observe largely consistent patterns of tissue-specific heritability enrichment for MS and IBDs in lung, spleen, whole blood and small intestine, and identify cell-type-specific enrichment for MS and IBDs in CD4+ T cells in lung and CD8+ cytotoxic T cells in lung and spleen. Our study sheds light on the biological basis of comorbidity between MS and IBD.
An epidemiological association between multiple sclerosis (MS) and inflammatory bowel disease (IBD) is well-established, but a genetic link is unclear. Here, the authors investigate the shared genetic architecture between MS and IBD to shed light on the biological basis of comorbidity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Mater Research, Translational Research Institute, Brisbane, Australia (GRID:grid.1064.3); Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
2 Mater Research, Translational Research Institute, Brisbane, Australia (GRID:grid.1064.3)
3 Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia (GRID:grid.1009.8) (ISNI:0000 0004 1936 826X); Neuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
4 Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); National Centre for Register-based Research, Aarhus University, Aarhus, Denmark (GRID:grid.7048.b) (ISNI:0000 0001 1956 2722)
5 Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia (GRID:grid.1009.8) (ISNI:0000 0004 1936 826X)
6 the First Affiliated Hospital of Anhui Medical University, Department of General Surgery, Hefei, China (GRID:grid.412679.f) (ISNI:0000 0004 1771 3402)